It is well accepted that cancer is caused by genetic alterations of oncogenes and tumor suppressor genes, and several signaling pathways through which these genes contributing to cancer act, have been uncovered. Recently, genome-wide profiling studies have revealed a remarkable heterogeneity of mutations among different patients affected by the same type of cancer. These studies have evidenced alteration of 'core pathways', which correspond to groups of proteins known to act together to form a signaling cascade and behave as a group of equivalence in which one mutation influences cell fate towards oncogenesis. 1, 2 However, it remains unclear whether genetic alterations of one core pathway functionally deregulate the others through the action of interconnecting nodes. Understanding this issue might offer the possibility of targeting these nodes, in addition to mutated signals within the core.
Receptor tyrosine kinase (RTK) signaling is one core pathway frequently altered in cancer. Over recent years, therapeutic approaches based on compounds selectively targeting oncogenic RTKs, to which cells are dependent, have been developed. 3 However, the success of these strategies has been limited since inhibition of the 'primary RTK addiction' triggers a selective pressure to acquire resistance through RTK switching. 4 As RTKs share several effectors that participate in the oncogenic process and in drug response, 5 an alternative strategy would rely on the identification of druggable signals required for RTK-triggered tumorigenesis.
In contrast to the genetic complexity of solid tumors, most chronic myeloid leukemias (CML) and a subset of acute lymphocytic leukemia (ALL) are caused by the oncoprotein BCR-ABL, to which cells are addicted for the execution of the oncogenic program. 6 The pivotal role of BCR-ABL in human leukemia has allowed the development of effective therapies using c-Abl-specific inhibitors such as Imatinib (Gleevec, Basel, Switzerland). 7 Although c-Abl activation by RTKs contributes to distinct biological responses, 8, 9 c-Abl oncogenic forms have been rarely identified in solid tumors. 10, 11 The still obscure role of c-Abl in this context is paralleled by the failure of using Abl antagonists for the treatment of solid tumors. 10, 11 It remains to be clarified whether a subset of tumors, identifiable by specific genetic or molecular signatures, would be highly sensitive to Abl inhibitors.
In this study, we asked whether c-Abl is aberrantly instructed and integrated in signaling mechanisms triggered by oncogenic RTKs by exploring c-Abl requirement in Mettriggered tumorigenesis. The Met-RTK and its ligand HGF have essential functions during embryogenesis and regenerative processes by regulating cell migration, survival, proliferation, and differentiation, similar to Met functions during the oncogenic processes, 4, [12] [13] [14] [15] [16] [17] and effective Met antagonists have been identified. 4, 18, 19 Moreover, Met confers resistance to ErbB antagonists, as cancer cells use Met to maintain the RTK-driven oncogenic pathways active. [20] [21] [22] Here, we show that genetic and pharmacological knockdown of c-Abl impairs Met-triggered solid tumor formation in vivo. By investigating the molecular mechanism involved, we identified a novel signaling path by which c-Abl interconnects RTKs and p53 core pathways. In particular, we show that c-Abl activation by Met triggers p53 phosphorylation on Ser 392 , which in turn drives the transcriptional upregulation of Mdm2 and protection from cell death. Finally, we uncovered a clinical correlation between aberrant Met activation, wild-type p53 phosphorylation on Ser 392 , and Mdm2 expression in human hepatocellular carcinoma (HCC). Our findings elucidate a molecular mechanism by which c-Abl participates in the oncogenic program driven by RTKs and may disclose a novel signaling signature to identify patients whose treatment may benefit from c-Abl inhibition.
Results c-Abl is required for survival and anchorage-independent growth of cancer cells dependent on oncogenic Met. To study whether c-Abl is a signaling node in oncogenic processes triggered by RTKs, we used GTL-16 human gastric carcinoma cells, in which constitutively activated Met leads to Met dependency for cell survival, anchorageindependent growth, and in vivo tumorigenesis. 23 We found that constitutive c-Abl phosphorylation on Tyr 412 was dependent on Met activity in GTL-16 cells (Figure 1a ). Mettriggered survival of GTL-16 cells was significantly reduced by c-Abl antagonists, in a dose-dependent manner (Figure 1b) . c-Abl requirement downstream of Met for cell survival was further confirmed by using shRNA interference approach (Figures 1b and e) , and found in other cancer cell lines. In particular, c-Abl phosphorylation on Tyr 412 was triggered by HGF in human HepG2 HCC cells (Supplementary Figure S1a) and c-Abl inhibition impaired HGF-induced HepG2 cell survival (Supplementary Figure S1b) . Imatinib and Nilotinib also inhibit PDGFR and Kit, in addition to c-Abl, 7 but we excluded them as primary targets as they were not expressed in all cell types used in our studies ( Supplementary Figures S1c and d) . We next evaluated in GTL-16 cells whether c-Abl was required for Met-triggered anchorage-independent growth, which is a hallmark of oncogenic transformation. c-Abl inhibition, either pharmacologically, through shRNA interference, or by using a kinase dead form (Abl KinÀ ), 24 severely affected Met-triggered anchorage-independent growth in a dose-dependent manner (Figures 1c-e) , indicating that c-Abl is required to execute the oncogenic transformation in cancer cells dependent on oncogenic Met.
Inhibition of c-Abl interferes with Met-triggered tumor growth in vivo. We next evaluated the requirement of c-Abl in Met-triggered tumor growth in vivo by depleting c-Abl using shRNA plasmids (Figure 2a) . We found that tumor growth caused by subcutaneous injection of HepG2 shAbl cells was significantly reduced compared with that induced by HepG2 control cells (Figures 2b and c) , which tumorigenesis has been demonstrated to be dependent on Met. 25 Similarly, we observed that c-Abl antagonists restrained Met-triggered tumor growth in vivo by following mice injected intraperitoneally with GTL-16 cells engineered for in vivo non-invasive bioluminescence imaging (Figure 2d ). Imatinib treatment led to a reduction of tumor weight by 49%, and of nodule number by 64% (sizeo2 mm) and 61% (size42 mm) (Figures 2e and f) . Taken together, these findings provide the first in vivo demonstration that c-Abl, when aberrantly instructed by oncogenic RTKs such as Met, is required for solid tumor growth.
c-Abl interconnects RTK and p53 core pathways by regulating Mdm2 gene expression. The observed major effect of c-Abl inhibition on Met-dependent cancer cells led us to hypothesize that c-Abl might act as molecular relay connecting core pathways. One of the most frequently altered core pathway evidenced by cancer genomic studies is centered on the tumor suppressor p53. We therefore asked whether c-Abl inhibition would affect the p53 core pathway by monitoring, as a readout of p53 transcriptional activity, expression of target genes such as Mdm2, cyclindependent kinase inhibitor p21 WAF1 , or Noxa. 26, 27 For this purpose, HepG2 cells (expressing the transcriptionally competent wild-type p53) were transfected with the luciferase reporter gene controlled by Mdm2, p21 WAF1 , or Noxa promoters, which are involved in cell survival, cell-cycle arrest, and apoptosis, respectively. Luciferase activity was measured in cells either treated with HGF or co-transfected with Abl PP active form. 28 We found that both HGF treatment and Abl PP expression selectively enhanced luciferase activity controlled by Mdm2, but not by p21 WAF1 or Noxa promoters (Figure 3a; Supplementary Figure S2a) . The selectivity of Met-Abl axis to upregulate Mdm2, but not p21 or Noxa, was further confirmed by western blot studies (Supplementary Figure S2b) . Importantly, the activity of the Mdm2-luciferase reporter was impaired in the presence of both c-Abl and p53 inhibitors (Figure 3a) .
Mdm2 overexpression is frequently observed in several tumors and contributes to tumorigenesis through p53-dependent and -independent mechanisms. 29, 30 Through a series of experimental settings, we evaluated Mdm2 regulation by the Met-Abl-p53 axis. Pharmacological impairment or shRNA interference of either c-Abl or p53 prevented Mdm2 upregulation in HepG2 cells exposed to HGF stimulation (Figures 3b-e c-Abl regulates p53 phosphorylation on Ser 392 , ensuring a qualitative readout of p53 transcriptional outcomes. We next investigated how c-Abl acted on p53 to regulate Mdm2 transcription in cells exposed to survival stimuli such as those emanating from Met. As p53 functions are highly modulated by post-translational modifications, 26, 31 we evaluated whether c-Abl inhibition would affect p53 phosphorylation. Basal low levels of p53 phosphorylation on Ser 15 and Ser 46 p53 phosphorylation on Ser 392 was also found in HepG2 cells exposed to HGF (Figure 5b) .
It has been shown that phosphorylation on Ser 392 leads to a p53 conformational change that enhances DNA binding and transcriptional activity. 31 We therefore ascertained whether p53 phosphorylation on Ser 392 was required for Met-Abltriggered Mdm2 transcriptional regulation by reconstituting either p53 wt or p53 S392A mutant in p53-deficient Hep3B cells. By following luciferase activity, we found that p53 S392A failed to trigger Mdm2-promoter induction in response to HGF, in contrast to p53 wt ( Figure 5c ; Supplementary Figure S4b ). Enhanced luciferase activity by HGF in Hep3B cells transfected with p53 wt was blocked in the presence of c-Abl antagonists (Figure 5c ). Furthermore, HGF induced p53 phosphorylation on Ser 392 and upregulation of endogenous Mdm2 levels in Hep3B cells transfected with p53 wt , but not with p53 S392A (Figure 5d ), thus demonstrating the requirement of p53 phosphorylation on Ser 392 for Mdm2 transcriptional regulation by the Met-Abl axis.
We next assayed whether p53 phosphorylation on Ser 392 enhances its DNA binding by performing chromatin immunoprecipitation studies in Hep3B cells transfected either with p53 wt or p53 S392A . We found higher basal levels of Mdm2 promoter bound to p53 wt compared with the p53 S392A mutant (Figure 5e ). Moreover, HGF increased the levels of Mdm2 promoter bound to p53
wt , but not to p53 S392A (Figure 5e ). Altogether, these findings indicate that c-Abl signaling by the Met-RTK regulates distinct p53 transcriptional outcomes through its phosphorylation on Ser 392 .
p38-MAPK links Met-Abl to p53 phosphorylation on Ser 392 and Mdm2 upregulation. We next investigated how c-Abl tyrosine kinase triggered p53 phosphorylation on Ser 392 . It has been reported that p38-MAPKs may regulate the phosphorylation of p53 on Ser 392 in nasopharyngeal carcinogenesis and in cells exposed to UV treatment. 26, 31 We previously reported that HGF stimulation leads to transient p38-MAPK phosphorylation in embryonic cells. 32 We therefore analyzed whether p38-MAPK signaling was required downstream of Met-Abl for p53 phosphorylation and Mdm2 expression. We found that phosphorylation of p38-MAPK was dependent on activated Met and c-Abl in GTL-16 cells (Figure 6a ). Inhibition of p38-MAPK interfered with p53 phosphorylation on Ser 392 and Mdm2 levels in GTL-16 cells (Figures 6a and b) . Moreover, c-Abl shRNA interference significantly reduced levels of Mdm2, p53 phosphorylation on Ser 392 , and p38 phosphorylation (Figures 6c and d) . Finally, low levels of Mdm2 and p53 phosphorylation on Ser 392 , but Figures S5a-c) . Altogether, these findings show that p38-MAPK signaling links Met-Abl activation to phospho-Ser 392 -p53 and Mdm2 upregulation.
Clinical correlation of phospho-Met, wild-type phosphoSer 392 -p53, and Mdm2 levels. The identification of a novel mechanism by which oncogenic Met regulates Mdm2 through Abl-p53 led us to determine whether there was a clinical correlation between oncogenic Met, phosphoSer 392 -p53, and Mdm2 levels in human tumors. We examined a total of 69 patient samples by applying a tumor array screening of human HCCs, where it has been reported that Met contributes to oncogenesis. 16, 33 We found that 35 samples (B50%) were positive for phospho-Met staining and 24 samples (B35%) for nuclear phospho-Ser 392 -p53 staining. Notably, 20/69 HCCs (B29%) showed coincidental immunoreactivity for both antigens. We next evaluated the p53 status in 20 double phospho-Met and phosphoSer 392 -p53 positive tumors, and found that p53 gene was mutated in only 6 HCCs (3 in exon 5, 3 in exon 7). Thus, 20/24 tumors positive for phospho-Ser 392 -p53 were also positive for phospho-Met, indicating that p53 phosphorylation was preferentially associated with the Met oncogenic state (Figure 7a ; Supplementary Table 1) .
We next evaluated Mdm2 levels in double phospho-Met/ phospho-Ser 392 -p53 positive HCCs by performing Q-RT-PCR and found a significant Mdm2 upregulation compared with controls (Figure 7b ; Supplementary Table 1) . Doublepositive cases were not associated with other clinicalpathological parameters (age, sex, etiology) nor with Mdm2 gene amplification, evaluated by FISH assay. A similar correlation between phospho-Met and wild-type phosphoSer 392 -p53 was also observed in 6/10 non-small-cell lung cancers. Thus, oncogenic Met and wild-type p53 phosphorylation on Ser 392 together with elevated Mdm2 levels in HCCs strongly supports a role for Met-Abl-p53-Mdm2 path in subpopulations of human cancers. 
Discussion
In this work, we showed that inhibition of c-Abl interferes with the Met-driven oncogenic program in vivo. Activated c-Abl signals through p38-MAPK to phosphorylate p53 on Ser 392 in cancer cells with an oncogenic Met. As a result, we observed a differential transcriptional modulation of p53 target genes, leading to the selective upregulation of the Mdm2 survival gene (Figure 8) . Notably, Mdm2 overexpression decreased the sensitivity of cancer cells to c-Abl antagonists. Our findings unveil the existence of a previously unrecognized mechanism by which RTKs modulate cell survival through c-Abl.
Aberrant activation of RTKs such as Met and ErbBs is associated with the evolution of several solid tumors, and their inhibition is deeply explored for molecular therapies. 4, [20] [21] [22] However, this strategy may not be fully effective since cells exposed to an inhibitor of the 'primary' activated kinase soon become resistant by a mechanism described as RTK switching. 4, [20] [21] [22] Our findings provide the first in vivo evidence that inhibition of c-Abl hampers the oncogenic program triggered by the activation of RTKs such as Met. The findings also suggest an alternative strategy to counteract oncogene dependency by targeting downstream signaling nodes, such as c-Abl, shared by several RTKs, [8] [9] [10] [11] which may therefore overcome resistance associated to RTK switching. Notably, protein-network-based strategies have revealed that some proteins, although not mutated, have important roles in interconnecting key signals in oncogenic processes. 34 Even though c-Abl genetic alterations are rarely found in solid tumors, 11 the identification of c-Abl as a mandatory passage in RTK-triggered oncogenesis designates it as a promising therapeutic target.
p53 transcriptional regulation depends on multiple factors such as the strength and reversibility of the stress, and the cellular context. 26, 27, 35 The p53 tumor suppressor function can be converted into tumor promoting by a few mutations found in tumors. 31, 35 Recent studies have shown that, rather than being a simple tumor suppressor gene, p53 is integrated in instructive signals to orchestrate developmental cell fate. 36, 37 Interestingly, it has been shown that while p53 acetylation is required for its transactivation activity on several p53 target genes, the Mdm2 promoter is regulated by p53 even in the absence of this post-translational regulation, suggesting that Mdm2 transcription by p53 may involve specific pathways. 38 We identified Ser 392 phosphorylation as a mechanism to specifically tune the expression of genes like Mdm2 and regulate cell survival. In contrast, Met does not modulate the phosphorylation of other Ser residues regulating p53 levels, which would be incompatible with tumorigenesis. Notably, in the cancer cell systems we have used, the increase Mdm2 levels do not impact significantly the basal levels of p53, which are, and remain, low compared with those found in cells exposed to agents triggering apoptosis, such as adriamycin. It has been shown that Abl activation may also trigger Mdm2 phosphorylation, which in turn impairs the inhibition of p53 by Mdm2. 39 Thus, c-Abl appears to modulate Mdm2 at multiple levels, and the signaling outcomes appear to be distinct from the well-known feedback loop on p53 regulation. Interestingly, our findings raise the provocative idea that oncogenic RTKs instruct wild-type p53 to participate in tumor evolution. Our results agree with those of recent studies aimed at uncovering the molecular mechanisms through which wild-type p53 activity is tuned in tumorigenesis. 40 Future work will clarify to which extent Ser 392 phosphorylation confers selectivity towards specific DNA sequences (and consequently target genes), which mechanisms are triggered by Mdm2 to impair cell death, and whether other signaling components are recruited within this path at different levels.
Although high levels of phospho-Ser 392 -p53 have been observed in tumors with mutant p53 and have been correlated with malignancy, 31 this phosphorylation in human tumors with wild-type p53 has been neglected so far. Our HCC array studies revealed that p53 was wild type in 70% of doublepositive phospho-Met/phospho-Ser 392 -p53, pointing to the path we have identified as a novel putative mechanism to modulate wild-type p53 function in cancer. These studies deserve further investigation to uncover the relationship between phospho-Ser 392 -p53 and deregulated RTK in solid tumors, and to clarify whether this correlation can be used as a signaling signature to identify those tumors that may be sensitive to c-Abl antagonists.
In summary, we introduce c-Abl as a signaling node interconnecting RTK and p53 core pathways, and provide clinical correlations between oncogenic Met, wild-type phospho-Ser 392 -p53, and Mdm2 levels in human tumors. Our findings point to c-Abl as a novel Achille's heel in RTK-dependent tumors with wild-type p53. Abl antagonists, while highly effective in some leukemias, have met little success when tested in patients affected by solid tumors. This failure, however, may be related to the molecular heterogeneity of the treated tumors. Here, we have identified a molecular signature that may help to discriminate which tumors could be sensitive to c-Abl inhibitors. Thus, the promise of c-Abl antagonists for combined treatment of solid tumors, either with traditional or with RTK-targeted agents, should deserve further evaluation according to tumor signaling signature. , IBDML) , 41 Pifithrin-a (p53 inhibitor), SU11274 (Met inhibitor), K252a (RTK inhibitor), z-DVED-fmk (Caspase inhibitor; Calbiochem). The concentrations of each inhibitor are the following; Imatinib (from 5 to 10 mM), Nilotinib (from 1 to 10 mM), SU11274 (from 0.1 to 5 mM), JLK1214 (10 mM), Pifithrina (from 1 to 10 mM), K252a (750 nM), SB202190 (from 1 to 10 mM), z-DVED-fmk (10 mM). No toxic effects were observed at the concentrations used. Actinomycin D (Sigma) was used at 0.2 mg/ml. DNA constructs. p53-HA-S 392 A was generated from pCDNA3-p53-HA using the QuickChange site-directed mutagenesis kit (Stratagene, Santa Clara, CA, USA), according to the manufacturer's instructions. pcDNA.Abl KinÀ and pcDNA.Abl PP have been previously described. 24, 28 psuper-shAbl and psupershp53 plasmids were generated according to the siRNA sequence previously described. Luciferase constructs were generated using mdm2, p21 WAF1 or Noxa promoters. pCMV-h-mdm2 plasmid was kindly provided by K Vousden.
Cell cultures. GTL-16, HepG2 cells with wild-type p53, 42 and p53-deficient Hep3B cells 43 , pools of resistant clones were used for biochemical and biological assays.
Biochemistry and quantitative real-time PCR. For biochemical studies, cell extracts, immunoprecipitations, and western blots were performed as described previously. 14, 15, 44 For quantitative real-time PCR, total RNA was extracted with Trizol (Invitrogen), according to the manufacturer's instructions. Reverse transcription was performed with Superscript Reverse Transciptase II (Invitrogen), according to the manufacturer's instructions. Levels of Mdm2 mRNA were measured by quantitative real-time PCR (qRT-PCR), based on TaqMan methodology, using the ABI PRISM 7500 Sequence Detection System (Applied Biosystems, Foster City, CA, USA), as previously described. 45 Briefly, customdesigned TaqMan primers and probes (Applied Biosystems) specific for Mdm2 were used. Results are expressed as relative units of target mRNA, referred to a sample called calibrator, chosen to represent 1 Â expression of the target gene. The calibrator used was the lowest value in the tissue collection under study. All analyzed samples express n-fold mRNA relative to the calibrator. Each sample mRNA was normalized relative to the b-actin mRNA. Pre-designed TaqMan primers and probe (Applied Biosystems) for the housekeeping gene b-actin were used. Each sample was treated with deoxyribonuclease (DNase) I amplification grade (Invitrogen), tested before and after DNase treatment.
Survival and anchorage-independent growth. For survival assays, GTL-16 cells were seeded in serum-free medium; inhibitors were applied 24 h later. HepG2 cells were seeded in medium containing 10% serum, starved for 24 h, and then inhibitors were applied. Viability was assessed with the Cell Titer Glo Luminescent Assay (Promega, Madison, WI, USA). Survival assays and anchorage-independent growth assays were performed as previously described. 14, 15, 18 Data on biological assays are representative of three independent experiments performed in duplicate.
In vivo tumorigenesis assays. Mice were kept at the IBDML animal facilities and all experiments were performed in accordance with institutional guidelines. Xenografts of GTL-16 luc cells were established by intraperitoneal (i.p.) injection of cells (10 6 ) in nude mice (S/SOPF SWISS NU/NU; Charles River, Wilmington, MA, USA). Mice were then treated daily with Imatinib (i.p. 50 mg/kg, according to the guidelines provided by Novartis Pharma AG) or vehicle. For in vivo bioluminescence imaging, after i.p. injection of luciferin (3 mg/mouse), mice were anesthetized and placed in the NightOwl LB981 (Berthold Technologies, Bad Wildbad, Germany) under continuous anesthetization (1.5-3% isoflurane in O 2 ). First, a black and white photographic image was acquired using 100 ms exposure. Next, the luminescent image was acquired using a 2-min photon integration period with background subtraction (pixel binning 8 Â 8). Analysis was performed using Berthold Technologies software. Mice were then killed after 20 days of treatment. Tumor nodules present in the peritoneal cavity were isolated and quantified according to their diameter and their total weight. Three independent tumorigenesis assays were performed (eight mice per group were used). For tumorigenesis assays with HepG2 pSuper and HepG2 shAbl cells, nude mice were inoculated subcutaneously into the flank/leg region with control pSuper or shAbl mutant cells. Tumor size was externally monitored every 3 days.
ChIP studies. Formaldehyde cross-linking and ChIP were performed as described previously.
46 p53-null Hep3B cells (0.5 Â 10 8 -1 Â 10 8 ) were transfected with 3 mg of p53 wt or p53 S392A expression vector, or with an empty vector pCDNA3 using lipofectamine 2000 reagent (Invitrogen). Cells were treated 24 h after transfection with or without HGF (50 ng/ml) for 20 min, washed with phosphatebuffered saline, and incubated for 10 min with 1% formaldehyde. After the reaction was quenched with 0.1 M glycine, the cells were sonicated into chromatin fragments with an average length of 500-800 bp. Immunoprecipitation was performed with protein G-Sepharose (Amersham Biosciences Corp., Uppsala, Sweden) and 3-5 mg of anti-p53 antibody (Ab7; Oncogene Science). The chromatin solution was precleared by incubation with protein G-Sepharose for 2 h at 41C, divided into aliquots, and incubated with the antibodies overnight at 41C. Before use, protein G-Sepharose was blocked twice at 41C with salmon sperm DNA (1 mg/ml) that had been sheared to a 500-bp length and BSA (1 mg/ml) for 2 h and overnight, respectively. Cross-linking was reversed by incubation of the eluate for 12 h at 651C with 200 mM NaCl. Finally, samples were treated with proteinase K (Invitrogen) and DNA was purified by extraction with phenol/chloroform and precipitated with isopropyl alcohol plus glycogen. The resulting DNA was analyzed by real-time PCR using following primers. Mdm2 promoter Forward: 5 0 -GCAGGTTGACTCAGCTTTTCCTCT-3 0 ; Mdm2 promoter Reverse: 5 0 -GTGGTTACAGCCCCATCAGTAGGTA-3 0 .
p53 mutations analysis. Only p-p53 nuclear immunoreactive cases were analyzed for p53 exons 5-8 mutations using SSCP analysis (single-strand conformational polymorphism analysis). Briefly, PCR amplification of exons 5, 6, 7, and 8 were done in 50 ml reaction volumes with a final concentration of 0.2 mmol/l deoxynucleotide triphosphates (Finnzymes), 0.2 mmol/l of each primer (Sigma), and 1 unit of Taq polymerase (Finnzymes). PCR products, denaturated in a buffer containing 100% formamide (Sigma), were run at room temperature on 15% acrylamide-bisacrylamide gel (Sigma) for 1 h at 100 V, and 4 h at 300 V. DNA containing the wild-type p53 (human placental DNA) was always included as negative control. Silver staining was done using PlusOne DNA Silver Staining kit (Amersham Biosciences Corp.), according to the manufacturer's instructions.
Tumor series under study and Immunohistochemistry. Sixty-nine cases of HCC resected at the Istituto Clinico Humanitas from 2004 to 2006 were analyzed. Clinicopathologial features are reported in Supplementary Table 1 . From the paraffin tissue of the single most representative tumor sample, four punches were obtained and collected on a tissue microarray (TMA). Standard 2 mm-thick sections of TMA were submitted to antigen retrieval (30 min at 981C in W-CAP TEC Buffer pH 8, Bio-Optica, Milano, Italy) and then incubated (1 h) with mouse monoclonal p-p53 (1 : 100; Novocastra Laboratories, New Castle upon Tyne, UK) or rabbit polyclonal p-Met (Tyr1230-1234-1235; 1 : 50; Assay Designs, Ann Arbor, MI, USA). The Immpress reagent was used as detection system (Vector Laboratories, Burlingame, CA, USA). Staining was obtained using 3,3 0 diaminobenzidine as chromogen followed by hematoxylin counterstaining. Positive (colorectal cancer) and negative (primary antibody omitted) controls were used. The nuclear p-p53 and the cytoplasmic p-Met immunoreactivity were evaluated as follows: negative -no or very weak/equivocal staining; positive -unequivocal staining. Total RNA purification from paraffin-embedded HCC samples was performed using Absolutely RNA FFPE
